Clinical Trial Update: TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL. [NA]

View source ↗

Summary

A completed pilot study comparing TC-325 (HEMOSPRAY) to standard care for malignant gastrointestinal bleeding to inform a future randomized controlled trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Gastrointestinal Bleeding

Drugs mentioned

• TC-325 (HEMOSPRAY) (TC-325)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: MALIGNANT GASTROINTESTINAL BLEEDING | NA | Status: COMPLETED